Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the place of nivolumab and pembrolizumab in the current treatment landscape for relapsed Hodgkin lymphoma. According to Prof Younes, the approval by the FDA is very specific and requires that patients have had a failed autologous stem cell transplant and brentuximab vedotin. He further discusses how the new combinations may change the treatment landscape.
Recorded at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, in Chicago, IL.

свернуть